<?xml version="1.0" encoding="UTF-8"?>
<p>It is imperative that international agencies formally recognize the high lethality of chikungunya in specific groups in order to reorient disease surveillance. Although usually a benign disease, chikungunya does not always have a self-limited clinical course. CHIKV infection and its complications can be the underlying cause of death or trigger a decompensation of preexisting medical conditions leading to a fatal outcome. Current chikungunya clinical protocols should be reviewed with the ultimate aim to prevent deaths [
 <xref rid="pntd.0007575.ref012" ref-type="bibr">12</xref>, 
 <xref rid="pntd.0007575.ref016" ref-type="bibr">16</xref>]. So far, France and Brazil have issued revised guidelines to manage chikungunya, following epidemics in the French South American and Pacific territories and in Brazil [
 <xref rid="pntd.0007575.ref003" ref-type="bibr">3</xref>, 
 <xref rid="pntd.0007575.ref018" ref-type="bibr">18</xref>]. However, contrary to dengue protocols, chikungunya management guidelines are not yet targeted to avoid fatal outcomes.
</p>
